Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Nat Rev Endocrinol 8:728742 Rosenstock J, Raccah D, Koranyi L et al (2013) Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X)
However, this change in medication hepatotoxicity is temporary
Strict Compliance Standards: We adhere fully to industry guidelines, supplying clearly labeled compounds strictly intended for authorized in vitro and laboratory research applications
Risk Factors of CJC-1295 CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analogue, has been investigated as a stimulant of GH and IGF-I secretion in healthy adults, who tolerated it well at doses of 30 or 60 microg/kg, although at 100 micro g/kg adverse reactions (mainly gastrointestinal) proved more frequent
Front Pharmacol 5:151 Stamler JS, Simon DI, Osborne JA, Mullins ME, Jaraki O, Michel T, Singel DJ, Loscalzo J (1992) S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds
Sigma-Aldrich, S1402-5G) 92
US$ 26.66
US$ 26.57
US$ 20.41
US$ 28.40
